Open AccessClinical efficacy and safety of alemtuzumab in postmarketing practice
Author(s) -
Н. В. Хачанова
Publication year - 2019
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2019-9-56-62
Subject(s) - alemtuzumab , adverse effect , medicine , dosing , postmarketing surveillance , intensive care medicine , multiple sclerosis , clinical trial , clinical practice , safety profile , patient safety , medical physics , pharmacology , physical therapy , health care , psychiatry , transplantation , economic growth , economics
Clinical trials confirm alemtuzumab efficacy for multiple sclerosis treatment in terms of both conventional measures and combined criteria such as NEDA (no evidence of disease activity). However, established drug efficacy and convenient dosing schedule are balanced by the risk of serious adverse events. Therefore, it is necessary to inform physicians about the benefits of alemtuzumab therapy along with the pattern of its safety profile.The present review provides the analysis of alemtuzumab real-world studies in Europe, USA and other parts of the world. The information obtained can help physicians to prescribe and administer the drug properly and to perform effective safety monitoring for early detection of adverse events and saving the maximum treatment benefit for the patient.